Dopavision Closes €12 Million Series A Round to Advance Digital Childhood Myopia Therapeutic Through Clinical Trials
– Seventure Partners and Novartis Pharmaceuticals join as new investors
– Transformative treatment for millions of children with myopia
Dopavision, a company pioneering the development of digital therapeutics, today announced the closing of a €12 million Series A financing round. Seventure Partners led the round and was joined by Novartis Pharmaceuticals and the Company´s existing shareholders such as Boehringer Ingelheim Venture Fund and Ababax Health, significantly broadening the Company’s shareholder base of leading international life science investors.
Neonatal Diagnostics Company InfanDx AG Completes Series A Funding
— Company raises EUR 4 million to reach key value-creating milestones over the next 12-18 months
— Klaus Albrecht, Alluti GmbH, appointed as new member of the Supervisory Board
InfanDx AG (Cologne, Germany), a privately held diagnostics company focusing on the development and commercialization of novel diagnostic solutions for newborns, today announced a first closing of a Series A financing round raising EUR 4 million from new and existing investors.
T-knife Therapeutics Announces the Appointment of Megan Baierlein as Chief Operating Officer
T-knife Therapeutics, Inc., a next-generation T-cell receptor company developing a pipeline of innovative therapeutics for solid tumor patients, today announced the appointment of Megan Baierlein as chief operating officer.
“We are excited to welcome Megan to our executive leadership team,” stated Thomas M. Soloway, chief executive officer of T-knife. “Megan has over two decades of experience building and leading successful life sciences companies, overseeing strategic planning, program management, and clinical operations functions. We look forward to the significant contributions that Megan will bring to T-knife as we advance our lead candidate TK-8001, targeting MAGE-A1 positive solid tumors, toward the clinic later this year and continue to advance our leading pipeline of novel TCR-T product candidates.”
